Abnormal MGMT Promoter Methylation May Contribute to the Risk of Esophageal Cancer: a Meta-analysis of Cohort Studies

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Jul 13

PMID 25015189

Citations 9

Authors

Jia-Jun Zhao

Hong-Yu Li

Di Wang

Hui Yao

Da-Wei Sun

Affiliations

Soon will be listed here.

Abstract

This meta-analysis was conducted aiming to evaluate the relationship between abnormal O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and the risk of esophageal cancer (EC). A range of electronic databases was searched: Web of Science (1945 ~ 2013), the Cochrane Library Database (Issue 12, 2013), MEDLINE (1966 ~ 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), and the Chinese Biomedical Database (CBM) (1982 ~ 2013) without language restrictions. Meta-analysis was performed with the use of the STATA 12.0 software. In the present meta-analysis, 9 clinical cohort studies with a total of 861 EC patients were included. The pooled results revealed that the frequency of MGMT promoter methylation in cancer tissues was significantly higher than in adjacent and normal tissues (cancer tissues vs adjacent tissues, odds ratio (OR) = 6.73, 95 % confidence intervals (95 % CI) 4.75 ~ 9.55, P < 0.001; cancer tissues vs normal tissues, OR = 13.68, 95 % CI 9.47 ~ 19.75, P < 0.001, respectively). Subgroup analyses by pathological type, ethnicity, and sample size suggested that abnormal MGMT promoter methylation also exhibited a higher frequency in all these subgroups (all P < 0.05). Our findings provide empirical evidence that abnormal MGMT promoter methylation may contribute to the risk of EC. Thus, detection of MGMT promoter methylation may be utilized as a valuable diagnostic marker for EC.

Citing Articles

Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in gastrointestinal cancers.

Wu Z, Dai J, Li J, Zhang Z, Shen X Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):319-327.

PMID: 39167167 DOI: 10.1007/s00210-024-03365-4.

Epigenetic editing and tumor-dependent immunosuppressive signaling in head and neck malignancies.

Gougousis S, Petanidis S, Poutoglidis A, Tsetsos N, Vrochidis P, Skoumpas I Oncol Lett. 2022; 23(6):196.

PMID: 35572491 PMC: 9100602. DOI: 10.3892/ol.2022.13317.

Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part II: A Cancer Risk Meta-Analysis.

Rapado-Gonzalez O, Martinez-Reglero C, Salgado-Barreira A, Santos M, Lopez-Lopez R, Diaz-Lagares A J Pers Med. 2021; 11(7).

PMID: 34206840 PMC: 8304899. DOI: 10.3390/jpm11070606.

Identification of DNA methylation-driven genes in esophageal squamous cell carcinoma: a study based on The Cancer Genome Atlas.

Lu T, Chen D, Wang Y, Sun X, Li S, Miao S Cancer Cell Int. 2019; 19:52.

PMID: 30886542 PMC: 6404309. DOI: 10.1186/s12935-019-0770-9.

A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma.

Nieto T, Tomlinson C, Dretzke J, Bayliss S, Price M, Dilworth M BMJ Open. 2018; 8(6):e020427.

PMID: 29961009 PMC: 6042533. DOI: 10.1136/bmjopen-2017-020427.

References

Guo M, Ren J, House M, Qi Y, Brock M, Herman J . Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2006; 12(15):4515-22. DOI: 10.1158/1078-0432.CCR-05-2858. View

Zhang L, Lu W, Miao X, Xing D, Tan W, Lin D . Inactivation of DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis. 2003; 24(6):1039-44. DOI: 10.1093/carcin/bgg062. View

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

Zintzaras E, Ioannidis J . HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005; 21(18):3672-3. DOI: 10.1093/bioinformatics/bti536. View

Crosbie P, McGown G, Thorncroft M, ODonnell P, Barber P, Lewis S . Association between lung cancer risk and single nucleotide polymorphisms in the first intron and codon 178 of the DNA repair gene, O6-alkylguanine-DNA alkyltransferase. Int J Cancer. 2007; 122(4):791-5. DOI: 10.1002/ijc.23059. View

Nozoe T, Korenaga D, Kabashima A, Sugimachi K . Smoking-related increase of O(6)-methylguanine-DNA methyltransferase expression in squamous cell carcinoma of the esophagus. Cancer Lett. 2002; 184(1):49-55. DOI: 10.1016/s0304-3835(02)00188-x. View

Dolan M, Schilsky R . Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002; 94(1):6-7. DOI: 10.1093/jnci/94.1.6. View

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

Hardikar S, Onstad L, Blount P, Odze R, Reid B, Vaughan T . The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One. 2013; 8(1):e52192. PMC: 3536789. DOI: 10.1371/journal.pone.0052192. View

10.

Srivenugopal K, Ali-Osman F . The DNA repair protein, O(6)-methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. Oncogene. 2002; 21(38):5940-5. DOI: 10.1038/sj.onc.1205762. View

11.

Peters J, Sutton A, Jones D, Abrams K, Rushton L . Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006; 295(6):676-80. DOI: 10.1001/jama.295.6.676. View

12.

Hochhauser D, Glynne-Jones R, Potter V, Gravalos C, Doyle T, Pathiraja K . A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013; 12(5):809-18. DOI: 10.1158/1535-7163.MCT-12-0710. View

13.

Huang S, Lee H, Mar K, Ji D, Huang M, Hsia K . Loss expression of O6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 109(6):883-9. DOI: 10.1016/j.tripleo.2009.12.019. View

14.

Wang J, Sasco A, Fu C, Xue H, Guo G, Hua Z . Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2008; 17(1):118-25. DOI: 10.1158/1055-9965.EPI-07-0733. View

15.

Doecke J, Zhao Z, Pandeya N, Sadeghi S, Stark M, Green A . Polymorphisms in MGMT and DNA repair genes and the risk of esophageal adenocarcinoma. Int J Cancer. 2008; 123(1):174-80. DOI: 10.1002/ijc.23410. View

16.

Fang M, Jin Z, Wang Y, Liao J, Yang G, Wang L . Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int J Oncol. 2005; 26(3):615-22. View

17.

Brock M, Gou M, Akiyama Y, Muller A, Wu T, Montgomery E . Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003; 9(8):2912-9. View

18.

Wang L, Zhu D, Zhang C, Mao X, Wang G, Mitra S . Mutations of O6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from Northern China. Int J Cancer. 1997; 71(5):719-23. DOI: 10.1002/(sici)1097-0215(19970529)71:5<719::aid-ijc5>3.0.co;2-u. View

19.

Christmann M, Tomicic M, Roos W, Kaina B . Mechanisms of human DNA repair: an update. Toxicology. 2003; 193(1-2):3-34. DOI: 10.1016/s0300-483x(03)00287-7. View

20.

Wei W, Yang J, Zhang S, Chen W, Qiao Y . [Analysis of the esophageal cancer mortality in 2004 - 2005 and its trends during last 30 years in China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2010; 44(5):398-402. View